AUSTIN, Texas, April 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived ...
Insight Molecular Diagnostics Inc. is rated Hold due to upcoming catalysts & pending FDA submission for GraftAssureDx. Read ...
Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
The test has been reported in peer‑reviewed journals such as Clinical Epigenetics and Biomolecules, and presented at major oncology conferences. EG BioMed’s CLIA and CAP accreditation enables U.S.
Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...
A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free DNA screening to test for chromosomal disorders can also reveal undetected ...
A new study may finally change how amyotrophic lateral sclerosis (ALS) is diagnosed. Scientists from UCLA Health and the University of Queensland developed a blood test that can spot signs of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback